An interventional study of Osteopathic protocol of Sphenopalatine Ganglion Stimulation in Dry Eye Disease and Xerostomia, sponsored by Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA. Completed at 1 site in Spain. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-11-01.
Sponsored by Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Dry Eye Syndromes with a site in Spain — 3 open to participants now, 4 under way, none of them phase 3. Dry Eye Syndromes · Spain.
Among the 44 studies in Dry Eye Syndromes with a site in Spain, this one is the 30th largest by enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2022, is one of 21 with no phase, and was the 25th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →3 of the 44 studies in Dry Eye Syndromes with a site in Spain are open now. Recruiting first, the newest first:
Barbara Burgos Blasco · Sites in Spain
Ages 18+
Laboratorios Thea, Spain · Sites in Spain
Ages 18+
NOXELIS · Sites in Spain
Ages 18–78
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 8 · Phase 4 5
First in 2009; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 41 interventional studies, 314 across the 3 observational. Of the 37 that completed or were terminated, 5 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 44 have an industry lead sponsor. The 10 most frequent:
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA has 5 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
2 of the studies in Dry Eye Syndromes with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928142Otsuka Pharmaceutical Development & Commercialization, Inc.A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's | 2027-03-13 |
| NCT07715266NOXELISPOST CATARACT SURGERY DRY EYE DISEASE | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Dry Eye Syndromes with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dry Eye Disease (DED) is a multifactorial pathology characterized by inflammation of the lacrimal functional unit that develops in ocular surface pathology, severely affecting patients quality of life. The core of the treatment relies at present in antinflammatory topical therapies, which are still scarce.
The investigators hypothesize that osteopathy-based techniques may help these patients by influencing the central involvement regarding parasympathetic innervation of tear and saliva-secreting glands.
The aim of this osteopathic treatment protocol is to release the involved structures in the tear-secreting system innervation, such as the sphenopalatine ganglion. In addition, this ganglion innervates the minor salivary glands, therefore it is intended to help patients suffering from xerostomia.
The hypothesis then is that a systemic protocol treatment can help balance both parts of the vegetative nervous system (sympathetic and parasympathetic) with the objective of increasing the secretion of tear and saliva in patients with ocular and oral dryness (DED and xerostomia, respectively), thus improving their clinical situation.
This osteopathic protocol does not have the potential to cause adverse effects. The main objective is to analyze the efficacy of this protocol application in terms of improving symptoms and signs of ocular and oral dryness, tear film quality and inflammation molecule levels in tears and saliva.
This clinical study intended to offer an alternative therapeutic tool for a disease, dry eye, that is highly prevalent, causes a decreased in the quality of life and work productivity, and whose pharmacologic treatment is very limited.
The osteopathy protocol consists of an initial assessment of the cranial vault and 7 techniques through which the different structures involved are treated and are as follows: 1) balance of the cranio-sacral system; 2) reharmonization of sphenobasilar synchondrosis; 3) and 4) release of the bony components in the pterygo-palatine fossa (maxillas and sphenoid); 5) and 6) release of the bony components in relation with the main lacrimal gland (frontal and front-malar suture); and 7) sphenopalatine ganglion stimulation. The patient is always in supine position and the investigator is standing on the side.
The proposed osteopathy protocol is innocuous, with no possible adverse effects. The main objective is to analyze the efficacy of this protocol application in terms of improving symptoms and signs of ocular and oral dryness, tear film quality and inflammation molecule levels in tears and saliva.
Recruited patients will have dry eye disease (and subsequently ocular dryness) and oral dryness (xerostomia). Inclusion/exclusion criteria are detailed in the corresponding section below, as well as all outcome measures.
All COVID19-related sanitary regulations will be strictly followed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Osteopathic protocol of sphenopalatine ganglion stimulation
Other: Osteopathic protocol of Sphenopalatine Ganglion Stimulation
Osteopathic protocol of sphenopalatine ganglion stimulation
Other: Osteopathic protocol of Sphenopalatine Ganglion Stimulation
Osteopathic protocol of sphenopalatine ganglion stimulation
Other: Osteopathic protocol of Sphenopalatine Ganglion Stimulation
Sphenopalatine Ganglion Stimulation to improve lacrimal and salivary gland secretion to improve ocular and oral dryness
Ocular Surface Disease Index (OSDI)
Score value 0-48, where higher score means a worse outcome.
Time frame: 6 Weeks
Ocular Surface Disease Index (OSDI)
Score value 0-48, where higher score means a worse outcome.
Time frame: 18 Weeks
Modified Single-Item Score Dry Eye-Questionnaire (mSIDEQ)
Score value 0-28, where higher score means a worse outcome
Time frame: 6 Weeks
Modified Single-Item Score Dry Eye-Questionnaire (mSIDEQ)
Score value 0-28, where higher score means a worse outcome
Time frame: 18 Weeks
Visual analogue Scale (VAS)
Unique measurements 0-10, where higher score means a worse outcome
Time frame: 6 Weeks
Visual analogue Scale (VAS)
Unique measurements 0-10, where higher score means a worse outcome
Time frame: 18 Weeks
Change in Dry Eye Symptoms Questionnaire (CDES-Q)
First question compares how the patient is at the moment compared with last session in terms of "Equal", "Better" or "Worse". If better or worse is chose, two more questions measure how much improvement or worsening from a 0-10 scale, where higher score means a worse outcome.
Time frame: 6 Weeks
Change in Dry Eye Symptoms Questionnaire (CDES-Q)
First question compares how the patient is at the moment compared with last session in terms of "Equal", "Better" or "Worse". If better or worse is chose, two more questions measure how much improvement or worsening from a 0-10 scale, where higher score means a worse outcome.
Time frame: 18 Weeks
Statistically significant amelioration in oral symptoms
Enhancement in Xerostomia Inventory Spanish version (XI-Sp) test score 0-11, where higher score means a worse outcome.
Time frame: 6 Weeks
Statistically significant amelioration in oral symptoms
Enhancement in Xerostomia Inventory Spanish version (XI-Sp) test score 0-11, where higher score means a worse outcome.
Time frame: 18 Weeks
Statistically significant improvement in tear secretion
Schirmer I test, which test score is 0-35 mm, where lower score means a worse outcome.
Time frame: 6 Weeks
Statistically significant improvement in tear secretion
Schirmer I test, which test score is 0-35 mm, where lower score means a worse outcome.
Time frame: 18 Weeks
Statistically significant improvement in salivary discharge
Salivary flow rate, where flow rate below 0,1ml flow is considered hyposalivation.
Time frame: 6 Weeks
Statistically significant improvement in salivary discharge
Salivary flow rate, where flow rate below 0,1ml flow is considered hyposalivation.
Time frame: 18 Weeks
Decrease in tear collection time
Statistically significant improvement in tear collection time, using a microcapillar of 1μl.
Time frame: 18 Weeks
Increased salivary flow rate
Statistically significant increased salivary flow rate, using Modified Fox Sreebny Technique.
Time frame: 18 Weeks
Lipiflow interferometry - lipid layer thickness
Statistically significant improvement in lipid layer thickness using Interferometry with Lipiview.
Time frame: 18 Weeks
Lipiflow interferometry - incomplete blink rate
Statistically significant improvement in incomplete blink rate using Interferometry with Lipiview.
Time frame: 18 Weeks
Lipiflow interferometry - c-factor
Statistically significant improvement in c-factor, using Interferometry with Lipiview.
Time frame: 18 Weeks
Enhancement in Break-Up Time Test
Statistically significant enhancement in Break-Up Time Test (normal \>7 seconds) where lower score means a worse outcome.
Time frame: 18 Weeks
Corneal Staining
Statistically significant enhancement in Corneal Staining, using Oxford Scale and Cornea and Contact Lens Research Unit (CCLRU) Scale, score 0-5 where higher scores means worse outcome.
Time frame: 18 Weeks
Significant beneficial change in molecules evaluated in tear or saliva
The following putative salivary indicators of pain are assayed by enzyme-linked immunosorbent assay (ELISA): Cortisol (DRG Salivary Cortisol ELISA (DRG Instruments GmbH, Marburg, Germany), testosterone (DRG Instruments GmbH), sTNFαRII (Quantikine, Human sTNF RII/TNFRSF1B Immunoassay, R\&D Systems, Minneapolis, MN, USA). sAA is
Time frame: 18 Weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2022 to primary completion in Oct 2024, 33 months.
Of 200 non-industry interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 25. This study's 33 months is above that.
Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA